Sickle Cell Disease Research, Surveillance,
Prevention & Treatment Act of 2015
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015
reintroduced in the House of Representatives
The Sickle Cell Disease Association of America, Inc., (SCDAA) along with its members, advocates and champions received tremendous news during the Annual Sickle Cell Disease Advocacy Day. On the morning of Thursday – April 16, 2015 Representatives Danny K. Davis (D-IL) and Michael C. Burgess (R-TX) revealed the reintroduction of bipartisan legislation to renew the nation’s programs for research, surveillance, prevention, and treatment of Sickle Cell Disease (SCD).
The Priority of the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015, H.R. 1807 is to improve quality of life, treatment, and prevention for those affected by Sickle Cell Disease. Among numerous modified benefits, the bill aims to establish full funding for twenty-five (25) Sickle Cell Treatment Centers throughout the US and provide continued support of a National Evaluation Center to collect, coordinate, monitor and distribute data, and to define best practice standards; development of treatment protocols and educational materials. Likewise, the bill requires continued authorization for community-based organization (CBO) collaborative programs to improve medical and support services delivered to affected individuals, and expanded eligibility beyond Federally Qualified Health Centers (FQHC). Furthermore, the bill seeks authorization for the Centers for Disease Control (CDC) to be the funding agency for the continuance and establishment of the Hemoglobinopathies Surveillance System program and SCD public health promotion initiatives.
WE NEED YOUR HELP!
Now is the time to reach out to your congressional leaders and request they sign and support this bill. Below is a toolkit of useful information to help you accomplish this goal. Visit the page below to view the current list of Cosponsors.
Click HERE to see if your local representative is on board.
TREATMENT ACT TRAINING BRIEFING & TRAINING PRESENTATION: